How Peptides Work in Your Body

Every cell in your body is sending and receiving messages constantly, and peptides are the language those messages are written in. Your body uses peptide-based signaling to regulate everything from hunger to healing to inflammation to sleep, which means that supplementing with peptide-based compounds is better understood as augmenting a conversation that is already happening rather than introducing something foreign to the system. This distinction matters because it changes how you evaluate safety, dosing, and the probability of side effects.

The most useful framework for understanding how peptides work comes from Dr. Abu Bakri, and it starts with one question: does this peptide have a known receptor?

The single most useful question you can ask about any peptide is whether it has a known receptor, because the answer determines everything about how you evaluate the compound.

Dr. Abu Bakri, Peptide Receptor Classification Framework, 2026

The answer determines everything about how you evaluate the compound. It is the single most useful question you can ask about any peptide you are considering. ¹

I · The molecules that fit into known locksThe molecules that fit into known locks

Some peptides have a known receptor, which means scientists have identified the specific protein on the surface of a cell that the peptide binds to with precision. GLP-1 agonists bind to the GLP-1 receptor on pancreatic beta cells and neurons in the brainstem. Tesamorelin binds to the GHRH receptor in the pituitary gland. Kisspeptin binds to the KISS1 receptor in the hypothalamus. ² When a peptide has a known receptor, its effects are predictable because researchers know exactly what happens after the binding event triggers the intracellular signaling cascade.

These peptides follow what pharmacologists call classical dose-response curves. A higher dose produces a stronger effect up to a plateau, after which adding more does nothing because all available receptors are occupied and saturated. The side effects are predictable from the receptor distribution in the body, so GLP-1 agonists cause nausea because GLP-1 receptors exist in the gut and brainstem at high density, not because of some obscure off-target toxicity that nobody saw coming. ³

The clinical development path for known-receptor peptides is well established because the regulatory framework fits the mechanism. Phase 1 trials establish safety in healthy volunteers, Phase 2 trials establish the optimal dosing range, and Phase 3 trials demonstrate efficacy against placebo or standard of care. This is why GLP-1 agonists have decades of peer-reviewed data and FDA approval while BPC-157 does not have either. The difference is not safety, it is whether the regulatory framework fits the mechanism of action.

II · The molecules that work without a known lockThe molecules that work without a known lock

Other peptides have no known receptor, which means no one has identified a specific protein binding site that explains their effects through the standard pharmacological framework. BPC-157, TB-500, GHK-Cu, and the Russian bioregulators like Epitalon all fall into this category. ⁴ They produce measurable biological effects across multiple systems, the evidence is clear that they work in living organisms, but the mechanism is broader and less specific than the classical lock-and-key model of receptor pharmacology.

BPC-157 appears to work through multi-protein complex modulation, interacting with several different cellular systems rather than binding to a single receptor. The Russian tetrapeptides like Epitalon bind to DNA grooves and alter chromatin accessibility, which means they change which genes your cells can read rather than sending a specific chemical signal across the cell membrane. ⁵ GHK-Cu chelates copper ions from the bloodstream, and the copper ion itself appears to be the active moiety that triggers collagen production and wound healing, making the peptide a delivery system for a mineral that has its own independent biological effects.

The safety profiles for no-known-receptor peptides come from case registries and cumulative clinical experience rather than from controlled trials. BPC-157 has over 16,000 documented cases in its safety registry, which is not as rigorous as a randomized controlled trial but provides more real-world data than many approved drugs had at the time of their initial approval. ⁶ The trade-off is that you cannot predict rare side effects in advance because you do not understand the mechanism well enough to anticipate what they might be.

III · What the receptor framework means for your protocolWhat the receptor framework means for your protocol

The practical implication of the Bakri framework is that you evaluate peptides differently depending on their category, and trying to use the same evaluation criteria for both categories produces confusion. For known-receptor peptides, the dosing is predictable from the published dose-response data, the side effects are known from the clinical trials, and the interaction risks are the same as any other drug that binds to a receptor. You follow the dosing guidelines, monitor for the known side effect profile, and do not stack two compounds that hit the same receptor because they will compete for binding rather than producing additive effects. ⁷

For no-known-receptor peptides, the dosing is empirical and based on community experience rather than controlled trials, the safety profile is derived from registry data rather than mechanistic prediction, and the interaction risks are lower because the compounds do not compete for specific binding sites and instead operate through broader, more distributed mechanisms. These peptides are harder to model pharmacologically but also less likely to produce the kind of acute interaction that would cause visible harm, which is why combinations like BPC-157 and TB-500 are widely used without documented negative interactions.

The Bakri framework does not tell you which peptides to use. It tells you how to think about the ones you are considering, and that distinction matters more than any specific protocol recommendation because it survives individual compounds coming and going. A framework is useful because it operates on the structure of the science rather than the marketing, and the question of whether a peptide has a known receptor will still determine how you evaluate it a decade from now when the specific brand names have changed and the landscape looks completely different.